Anat Mirelman1,2, Rachel Saunders-Pullman3,4, Roy N Alcalay5, Shiran Shustak1, Avner Thaler1,2, Tanya Gurevich1,2, Deborah Raymond3, Helen Mejia-Santana5, Martha Orbe Reilly5, Laurie Ozelius4, Lorraine Clark5,6, Mali Gana-Weisz7, Anat Bar-Shira7, Avi Orr-Utreger2,7, Susan B Bressman3,4, Karen Marder5, Nir Giladi1,2. 1. Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel. 2. Sackler School of Medicine, Sagol School for Neuroscience, Tel Aviv University, Tel-Aviv, Israel. 3. Departments of Neurology, Mount Sinai Beth Israel Medical Center, New York, New York, USA. 4. Icahn School of Medicine at Mount Sinai, New York, New York, USA. 5. Department of Neurology, College of Physicians and Surgeons, Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA. 6. Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA. 7. Genetics Institute, Tel Aviv Medical Center, Tel Aviv, Israel.
Abstract
BACKGROUND: In 2015, the International Parkinson and Movement Disorder Society Task Force recommended research criteria for the estimation of prodromal PD. OBJECTIVES: We aimed to evaluate, for the first time, the criteria in first-degree relatives of Ashkenazi Jewish G2019S-LRRK2 PD patients, who are considered a population at risk for developing PD, and assess the sensitivity and specificity of the criteria in identifying phenoconverters. METHODS: Participants were evaluated longitudinally over a period of 5 years (average follow-up: 49.2 ± 12.3 months). Likelihood ratios and probability estimations were calculated based on the International Parkinson and Movement Disorder Society Research Criteria for Prodromal Parkinson's Disease markers and examined for each assessment point. RESULTS: One hundred twenty healthy carriers (49.53 ± 13.4 years; 54% female) and 111 healthy noncarriers (48.43 ± 15.79 years; 49% female) participated in this study. Probability scores were significantly higher in healthy carriers than healthy noncarriers (P < 0.0001). Of the 20 participants (8.6%) who met criteria for probable prodromal PD at baseline, 17 were healthy carriers. Participants who reached the threshold were older (P < 0.0001), had higher UPDRS-III (P < 0.001), lower cognitive function (P = 0.001), and more nonmotor symptoms (P < 0.0001), compared to those who did not. Ten participants were diagnosed with incident PD within 5 years from baseline resulting in a specificity of 91.82% (95% confidence interval: 86.69-96.94), sensitivity of 80% (95% confidence interval: 55.21-100), positive predictive value of 47.06% (95% confidence interval: 23.33-70.79), and negative predictive value of 98.06% (95% confidence interval: 95.39-100). All 10 phenoconvertors were G2019S-LRRK2 carriers. CONCLUSIONS: The results showed the utility of using the criteria and high sensitivity and specificity in identifying prodromal PD in this high-risk unique cohort. These results may be valuable for future disease modification clinical trials.
BACKGROUND: In 2015, the International Parkinson and Movement Disorder Society Task Force recommended research criteria for the estimation of prodromal PD. OBJECTIVES: We aimed to evaluate, for the first time, the criteria in first-degree relatives of Ashkenazi Jewish G2019S-LRRK2PDpatients, who are considered a population at risk for developing PD, and assess the sensitivity and specificity of the criteria in identifying phenoconverters. METHODS:Participants were evaluated longitudinally over a period of 5 years (average follow-up: 49.2 ± 12.3 months). Likelihood ratios and probability estimations were calculated based on the International Parkinson and Movement Disorder Society Research Criteria for Prodromal Parkinson's Disease markers and examined for each assessment point. RESULTS: One hundred twenty healthy carriers (49.53 ± 13.4 years; 54% female) and 111 healthy noncarriers (48.43 ± 15.79 years; 49% female) participated in this study. Probability scores were significantly higher in healthy carriers than healthy noncarriers (P < 0.0001). Of the 20 participants (8.6%) who met criteria for probable prodromal PD at baseline, 17 were healthy carriers. Participants who reached the threshold were older (P < 0.0001), had higher UPDRS-III (P < 0.001), lower cognitive function (P = 0.001), and more nonmotor symptoms (P < 0.0001), compared to those who did not. Ten participants were diagnosed with incident PD within 5 years from baseline resulting in a specificity of 91.82% (95% confidence interval: 86.69-96.94), sensitivity of 80% (95% confidence interval: 55.21-100), positive predictive value of 47.06% (95% confidence interval: 23.33-70.79), and negative predictive value of 98.06% (95% confidence interval: 95.39-100). All 10 phenoconvertors were G2019S-LRRK2 carriers. CONCLUSIONS: The results showed the utility of using the criteria and high sensitivity and specificity in identifying prodromal PD in this high-risk unique cohort. These results may be valuable for future disease modification clinical trials.
Authors: Rachel Saunders-Pullman; Richard B Lipton; Geetha Senthil; Mindy Katz; Camille Costan-Toth; Carol Derby; Susan Bressman; Joe Verghese; Laurie J Ozelius Journal: Neurosci Lett Date: 2006-04-24 Impact factor: 3.046
Authors: Ronald B Postuma; Dag Aarsland; Paolo Barone; David J Burn; Christopher H Hawkes; Wolfgang Oertel; Tjalf Ziemssen Journal: Mov Disord Date: 2012-04-15 Impact factor: 10.338
Authors: Daniela Berg; Ronald B Postuma; Charles H Adler; Bastiaan R Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl Journal: Mov Disord Date: 2015-10 Impact factor: 10.338
Authors: Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman Journal: N Engl J Med Date: 2006-01-26 Impact factor: 91.245
Authors: Philipp Mahlknecht; Arno Gasperi; Peter Willeit; Stefan Kiechl; Heike Stockner; Johann Willeit; Gregorio Rungger; Martin Sawires; Michael Nocker; Verena Rastner; Katherina J Mair; Anna Hotter; Werner Poewe; Klaus Seppi Journal: Mov Disord Date: 2016-06-06 Impact factor: 10.338
Authors: Rachel Saunders-Pullman; Roy N Alcalay; Anat Mirelman; Cuiling Wang; Marta San Luciano; Roberto A Ortega; Amanda Glickman; Deborah Raymond; Helen Mejia-Santana; Nancy Doan; Brooke Johannes; Kira Yasinovsky; Laurie Ozelius; Lorraine Clark; Avi Orr-Utreger; Karen Marder; Nir Giladi; Susan B Bressman Journal: Mov Disord Date: 2015-09-14 Impact factor: 10.338
Authors: Cameron Miller-Patterson; Jesse Y Hsu; Lana M Chahine; James F Morley; Allison W Willis Journal: Clin Auton Res Date: 2022-09-03 Impact factor: 5.625
Authors: Alessandra Fanciulli; Fabian Leys; Fabienne Lehner; Victoria Sidoroff; Viktoria C Ruf; Cecilia Raccagni; Philipp Mahlknecht; Demy J S Kuipers; Wilfred F J van IJcken; Heike Stockner; Thomas Musacchio; Jens Volkmann; Camelia Maria Monoranu; Iva Stankovic; Guido Breedveld; Federico Ferraro; Christina Fevga; Otto Windl; Jochen Herms; Stefan Kiechl; Werner Poewe; Klaus Seppi; Nadia Stefanova; Sonja W Scholz; Vincenzo Bonifati; Gregor K Wenning Journal: Brain Commun Date: 2022-07-04
Authors: Tanya Simuni; Liz Uribe; Hyunkeun Ryan Cho; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Duygu Tosun; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha J Hutten; Susan Bressman; Kenneth Marek Journal: Lancet Neurol Date: 2019-10-31 Impact factor: 44.182
Authors: Daniela Berg; Per Borghammer; Seyed-Mohammad Fereshtehnejad; Sebastian Heinzel; Jacob Horsager; Eva Schaeffer; Ronald B Postuma Journal: Nat Rev Neurol Date: 2021-04-20 Impact factor: 42.937
Authors: Alicia Garrido; Graham Fairfoul; Eduardo S Tolosa; Maria José Martí; Alison Green Journal: Ann Clin Transl Neurol Date: 2019-05-09 Impact factor: 4.511